This analysis reveals a troubling consolidation in phase I NSCLC clinical trials, where high-volume sites in major cities dominate while smaller, often community-based sites decline. The strongest version of this narrative highlights legitimate structural barriers—complex protocols, regulatory hurdles, and the self-reinforcing cycle of expertise and sponsorship—that disadvantage smaller sites. The FDA’s push for decentralization clashes with the practical realities of modern oncology research, w...